CytoSorbents Corporation (CTSO)

[pharmeng]

BMA, I think it was a good call to sell. I unfortunately did not get a chance before it fell below $9, so I'm still holding, fortunately at a $5.60 cost at least.

I'm still not sure how you can say fundamentally nothing is wrong. The market cap was over 300 million, you're talking about probably <2 million sales in first half of this year to support that?

Now, the next quarter that might be good, is Q3, so we'll be waiting until October.

If there was concrete clinical data, sales would be starting in the tens of millions, and accelerating from there, not from a few hundred thousand dollars.